State Street’s Benitec Biopharma BNTC Stock Holding History

State Street’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.06M	Buy	377,973 +39,724	+12%	+$471K	﹤0.01%	3003
2026 Q1	$3.6M	Buy	338,249 +93,198	+38%	+$1.08M	﹤0.01%	3087
2025 Q4	$3.3M	Buy	245,051 +26,653	+12%	+$369K	﹤0.01%	3160
2025 Q3	$3.06M	Buy	218,398 +57,325	+36%	+$732K	﹤0.01%	3191
2025 Q2	$1.88M	Buy	161,073 +139,883	+660%	+$1.96M	﹤0.01%	3336
2025 Q1	$276K	Buy	21,190 +5,100	+32%	+$61.7K	﹤0.01%	3749
2024 Q4	$203K	Buy	+16,090	New	+$174K	﹤0.01%	3850
2023 Q3	–	Sell	-1,261	Closed	-$5.11K	–	4564
2023 Q2	$5.11K	Hold	1,261	–	–	﹤0.01%	4663
2023 Q1	$4.5K	Hold	1,261	–	–	﹤0.01%	4771
2022 Q4	$3.64K	Hold	1,261	–	–	﹤0.01%	4841
2022 Q3	$8K	Hold	1,261	–	–	﹤0.01%	4900
2022 Q2	$25K	Hold	1,261	–	–	﹤0.01%	4850
2022 Q1	$50K	Buy	1,261 +26	+2%	+$1.08K	﹤0.01%	4790
2021 Q4	$55K	Hold	1,235	–	–	﹤0.01%	4684
2021 Q3	$75K	Hold	1,235	–	–	﹤0.01%	4600
2021 Q2	$89K	Buy	+1,235	New	+$96.6K	﹤0.01%	4382

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

State Street's BNTC Position: Q2 2026 in Review

State Street increased its Benitec Biopharma (BNTC) stake by 12% in Q2 2026, buying an estimated $471K and bringing the position to 377,973 shares worth $5.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

State Street first reported a position in BNTC in Q2 2021 and has held it in 16 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

State Street held 377,973 shares of Benitec Biopharma worth $5.06M as of Q2 2026.
State Street bought 39,724 Benitec Biopharma shares in Q2 2026, an estimated $471K.
Benitec Biopharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3003 holding.
State Street first reported a position in Benitec Biopharma in Q2 2021 and has held it in 16 quarters since.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.